Search results for "Antiresorptive Agents"

showing 4 items of 4 documents

2014

ABSTRACT: Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases,…

Cancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)CancerGeneral Medicinemedicine.diseaseSurgeryDenosumabOncologyInternal medicineAntiresorptive AgentsEpidemiologymedicinebusinessOsteonecrosis of the jawMultiple myelomaReduction (orthopedic surgery)medicine.drugFuture Oncology
researchProduct

Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease

2014

AbstractManagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate th…

AdultMaleCutaneous FistulaSettore MED/50 - Scienze Tecniche Mediche ApplicateDental Fistulastaging system; bisphosphonate; computed tomography; aaoms; osteonecrosis of the jaw; antiresorptive agentsAAOMSAntiresorptive agentSettore MED/29 - Chirurgia MaxillofaccialeAAOMS Antiresorptive agents Bisphosphonate Computed tomography Osteonecrosis of the jaw Staging systemBronj; AAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemSettore MED/28 - Malattie OdontostomatologicheMandibular FracturesBronjOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAlveolar ProcessHumansBisphosphonateMandibular DiseasesComputed tomographyAgedRetrospective StudiesAged 80 and overSuppurationBone Density Conservation AgentsOsteonecrosis of the jawPatient AcuityAntiresorptive agentsCone-Beam Computed TomographyMiddle AgedStaging systemMaxillary DiseasesPhenotypeOtorhinolaryngologyTooth ExtractionBisphosphonate-Associated Osteonecrosis of the JawDrug Therapy CombinationFemaleSurgeryOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemOral SurgeryTomography X-Ray ComputedTomography Spiral ComputedOsteosclerosis
researchProduct

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents

2015

Background The clinical management of medication-related osteonecrosis of the jaw (MRONJ) in patients treated with bisphosphonates and other antiresorptive agents is subject to controversy. The American Association of Oral and Maxillofacial Surgeons (AAOMS) has developed guidelines for the correct management of the disorder which are revised and updated by a panel of experts. Material and Methods The present systematic review analyzes the different treatments currently used to treat this clinical condition, based on the PRISMA® (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement published in 2009. An electronic Medline search was made of the PubMed database, cover…

medicine.medical_specialtyMEDLINEAlternative medicineDentistryDiseaseReview03 medical and health sciences0302 clinical medicineAntiresorptive AgentsmedicineHumansStage (cooking)Intensive care medicineGeneral DentistryBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngology030220 oncology & carcinogenesisTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jaw
researchProduct

2015

Recent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who present with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed because their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre study on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of a large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and non-exposed ONJ…

medicine.medical_specialtyPediatricsBisphosphonate-associated osteonecrosis of the jawCross-sectional studybusiness.industryOsteoporosisLarge populationmedicine.diseaseSurgeryExact testOtorhinolaryngologySecondary analysisAntiresorptive AgentsmedicineSurgeryOral SurgeryOsteonecrosis of the jawbusinessBritish Journal of Oral and Maxillofacial Surgery
researchProduct